Mandate

Vinge advises Bergs Timber AB in connection with its in kind acquisition of Jarl Timber AB

July 19, 2016

Vinge has advised Bergs Timber AB (publ) (”Bergs Timber”) on capital markets issues in connection with its acquisition of Jarl Timber AB.

The acquisition was approved by the annual general meeting of shareholders in Bergs Timber on June 28, 2016. The acquisition of the shares in Jarl Timber AB was made by an issue in kind where the purchase price consisted of 46 338 430 newly issued shares in Bergs Timber. The newly issued shares were admitted to trading on Nasdaq Stockholm, Small Cap, on July 12, 2016.

Bergs Timber produces and sells sawn and processed timber products with an emphasis on the construction market. Total sawmill capacity under the current production structure is approximately 345,000 m³ of sawn timber, of which more than half is processed. The Group offers a full range of silvicultural services, ranging from advising forest owners to clear felling.

Vinge’s team primarily consisted of Jesper Schönbeck, David Andersson and Joel Wahlberg.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026